Transforming cryoablation cancer treatment with ProSense™
NEW CLINICAL RESULTS
Published results in Israel treating recurrent kidney tumors after primary nephron-sparing surgery demonstrated a 100% oncologic success in 7 patients. No tumors showed contrast enhancement or growth on follow-up imaging.
IceCure is currently establishing strong clinical foundations in interventional oncology to enable ProSense™ treatment for cancer of the kidney and additional applications.
Clinical trials treating kidney cancer percutaneously under CT with ProSense™ cryoablation are indicating exceptional outcomes in Israel.
Jason R. Williams, MD
Director of Interventional Oncology,
Williams Cancer Institute,
Atlanta, GA and Mexico City, Mexico
Clinical studies with ProSense™ are currently underway at centers of excellence worldwide.
ProSense™ Treatment of Renal Cancer
Ongoing trial and collaborative clinical
 Shprits S. et al., 2019 Cryoablation for recurrent renal tumors after primary nephron-sparing surgery using an innovative liquid nitrogen-based cryogenic device.
Journal of Molecular and Clinical Medicine: 2 (1):11-14.
New published results
Of 7 patients with tumor recurrence after nephron-sparing surgery, none of the treated tumor lesions demonstrated
contrast enhancement or growth on follow up imaging indicating a 100% oncologic success. Only three adverse events were recorded.
Investigators found cryoablation with the ProSense™ system is feasible and effective, with excellent renal function preservation and without major complications. 
Of 74 patients with 78 small kidney masses (≤ 4cm) treated, ProSense™ showed treatment success by lack of enhancement on CT or MRI in 93% (42 of 45) of cases at 1 year follow-up. Investigators found the ProSense™ system to be safe, effective and without serious adverse events.